Australian Clinical Labs (ACL) AGM 2024 summary

Opening remarks and agenda

• Chair welcomed participants, acknowledged traditional custodians, and confirmed quorum for the meeting.

• Board members, executive team, company secretary, and auditor were introduced, with the auditor available for questions on financial statements.

• Voting and Q&A procedures for the virtual AGM were explained, including technical contingency plans.

• Agenda included the chair's address, CEO's operational and financial review, formal business, and Q&A.

Financial performance review

• FY24 revenue was $696.4M, matching guidance and prior year despite a 59–60% drop in COVID revenue.

• Non-COVID revenue rose 5.4% to $646.7M, with H2 up 6.9% over the prior period.

• Underlying EBITDA was $191M, up 1.3% year-on-year; underlying EBIT was $62.6M, with an 11% margin.

• Underlying NPAT was $31.6M; free cash flow before interest, tax, and financing increased 4% to $54.4M.

• FY25 EBIT guidance reconfirmed at $65M–$73M, with 6% YTD volume growth as of 23 October.

Board and executive committee updates

• Two board members, Andrew Dutton and Nathanial Thomson, are retiring; recruitment for new members is underway with announcements expected before Christmas.

• Michael Alscher stood for and was recommended for re-election as Chair, with the board citing his expertise and continuity.